Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Kayvon Modjarrad, Christine C. Roberts*, Kristin T. Mills, Amy R. Castellano, Kristopher Paolino, Kar Muthumani, Emma L. Reuschel, Merlin L. Robb, Trina Racine, Myoung don Oh, Claude Lamarre, Faraz I. Zaidi, Jean Boyer, Sagar B. Kudchodkar, Moonsup Jeong, Janice M. Darden, Young K. Park, Paul T. Scott, Celine Remigio, Ajay P. ParikhMegan C. Wise, Ami Patel, Elizabeth K. Duperret, Kevin Y. Kim, Hyeree Choi, Scott White, Mark Bagarazzi, Jeanine M. May, Deborah Kane, Hyojin Lee, Gary Kobinger, Nelson L. Michael, David B. Weiner, Stephen J. Thomas, Joel N. Maslow

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

241 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial'. Together they form a unique fingerprint.

Medicine & Life Sciences